engerix b stungulyf, dreifa
glaxosmithkline pharma a/s - lifrarbólgu b yfirborðsmótefnavaki - stungulyf, dreifa
brimica genuair
covis pharma europe b.v. - formoterol fumarate dihydrate, aclidinium bromide - lungnasjúkdómur, langvarandi hindrandi - lyf til veikindi öndunarvegi sjúkdómum, - brimica genuair er ætlað til meðferðar við berkjuvíkkandi meðferð við loftflæði hindrun og léttir einkenni hjá fullorðnum sjúklingum með langvarandi lungnateppu (copd).
duaklir genuair
covis pharma europe b.v. - genuair brómíð, formóteróli fúmarat tvíhýdrat - lungnasjúkdómur, langvarandi hindrandi - lyf til veikindi öndunarvegi sjúkdómum, - duaklir genuair er ætlað til meðferðar við berkjuvíkkandi meðferð til að létta einkenni hjá fullorðnum sjúklingum með langvinna lungnateppu (copd).
replagal
takeda pharmaceuticals international ag ireland branch - agalsídasi alfa - fabry sjúkdómur - Önnur meltingarvegi og efnaskipti vörur, - replagal er ætlað til langtíma ensím-skipti meðferð í sjúklinga með staðfest greining fabry sjúkdómur (a-galactosidase-skort).
myleran filmuhúðuð tafla 2 mg
aspen pharma trading limited - busulfanum inn - filmuhúðuð tafla - 2 mg
valaciclovir bluefish filmuhúðuð tafla 500 mg
bluefish pharmaceuticals ab - valaciclovirum hýdróklóríð - filmuhúðuð tafla - 500 mg
venlafaxine bluefish hart forðahylki 150 mg
bluefish pharmaceuticals ab - venlafaxinum hýdróklóríð - hart forðahylki - 150 mg
venlafaxine bluefish hart forðahylki 37,5 mg
bluefish pharmaceuticals ab - venlafaxinum hýdróklóríð - hart forðahylki - 37,5 mg
venlafaxine bluefish hart forðahylki 75 mg
bluefish pharmaceuticals ab - venlafaxinum hýdróklóríð - hart forðahylki - 75 mg
clopidogrel viatris (previously clopidogrel taw pharma)
viatris limited - clopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - blóðþurrðandi lyf - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). l hækkun, bráð myndun stíflufleygs, ásamt asa í læknisfræðilega sjúklingum rétt fyrir segaleysandi meðferð. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. nánari upplýsingar er að vísa til kafla 5.